Apollomics Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Apollomics
Pharmaceutical Preparations, SIC 2834
Apollomics Inc. is a clinical-stage biopharmaceutics enterprise focused on the discovery and clinical advancement of oncology therapies. The organization concentrates on advancing drug candidates designed to address challenging and resistant cancers by leveraging pipeline developments, research licensing agreements, and drug supply collaborations. Its clinical and research programs aim to meet patient needs across global oncology markets, engaging with international healthcare institutions and pharmaceutical research partners.
The company maintains operational activities and corporate presence across several territories, including the United States, Australia, China, and Hong Kong. It is organized under the laws of the Cayman Islands. Apollomics Inc. oversees its global administration from its principal executive offices located in Foster City, California.
Summary of the business section of Apollomics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Apollomics Inc.
- Founded
- 2015
- Headquarters
- Covina, CA
- Address
- 668 Arrow Grand Cir, Suite 206 91772
- Phone
- 1-650-209-4055
- Website
- apollomicsinc.com
- Employees
- 14, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, San Francisco, California
Stock & identifiers
- Ticker
- APLM
- Other tickers
- APLMW
- Exchange
- Nasdaq
- IPO date
- Nov 26, 2021
- Shares outstanding
- 2M, Apr 24, 2026
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-100 reverse, Nov 25, 2024
- SEC CIK
- 1944885
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yi-Kuei Chen | Chief Operating Officer, Director | 141,348 |
| Hung-Wen Chen | Chief Executive Officer, Director | 1,453,029 |
| Peter Kuan-How Lin | Chief Financial Officer | 58,979 |
| Hung Hsien Yen | Director | 500 |
| Ya-Chi Huang | Director | 1,500 |
| Hsien-Shu Tsai | Director | 2,000 |
| Hong-Jung Chen | Director | 4,120 |
| Yi-An Chu | Director | 1,500 |
| Chen-Huan Jan | Director | 1,500 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 14 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 28, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 22, 2022 | Merger | Registration of securities for a merger or exchange offer (S-4) |